Sarah Gregory
Acute Care · Cleveland, TNNPI 1881060002
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,818 of the $8,976 with a category attached, or 76.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,053 and has fallen 69.4% since, to $1,242 in 2025. Among acute care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$748
- Amgen$746
- Novartis$619
- Johnson & Johnson$574
- plus $3K from 24 others
What the payments were for
- Travel & lodging$2,07923%
- Food & beverage$6,81876%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 20 | $1,763 |
| Medtronic | 20 | $1,588 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 42 | $748 |
| Amgen | 30 | $746 |
| Novartis | 37 | $619 |
| Johnson & Johnson | 28 | $574 |
| AstraZeneca(2 entities) | 26 | $523 |
| Actelion Pharmaceuticals US, Inc. | 13 | $515 |
| Boehringer Ingelheim | 17 | $296 |
| Merck | 12 | $226 |
| Pfizer | 13 | $222 |
| E.r. Squibb & Sons, L.L.C. | 13 | $221 |
| Scpharmaceuticals Inc. | 9 | $190 |
| Novo Nordisk | 6 | $167 |
| Lantheus Medical Imaging, Inc. | 1 | $98 |
| Bayer | 5 | $92 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Kestra Medical Technology Services, Inc. | 3 | $51 |
| Baxter Healthcare | 2 | $32 |
| Abbott | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| GRT US Holding, Inc. | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $22 |
| Cvrx, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Cashflow Solutions, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,976 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $117,713 |
| EntrestoSacubitril/Valsartan | 64 | $73,272 |
| XareltoRivaroxaban | 39 | $42,657 |
| JardianceEmpagliflozin | 30 | $40,209 |
| FarxigaDapagliflozin Propanediol | 19 | $22,860 |
| BrilintaTicagrelor | 20 | $21,166 |
| Repatha SyringeEvolocumab | 12 | $12,939 |
| Metoprolol Succinate | 188 | $2,407 |
| Ranolazine ErRanolazine | 21 | $1,317 |
| Atorvastatin Calcium | 118 | $1,200 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $1,133 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 12 | $1,084 |
| Potassium Chloride | 72 | $796 |
| Carvedilol | 124 | $774 |
| Flecainide Acetate | 18 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $222 | $117,713107 claims |
| NovartisEntresto | $619 | $73,27264 claims |
| AstraZenecaFarxiga, Brilinta | $523 | $44,02639 claims |
| Johnson & JohnsonXarelto | $574 | $42,65739 claims |
| Boehringer IngelheimJardiance | $296 | $40,20930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.
Other acute care in Cleveland
- Amber AndersonCleveland$9K
- Haley HoyNashville$368K
- Anne AlexandrovMemphis$110K
- Stephen MillerKnoxville$108K
- Shannon GraceNashville$57K
- Timothy BallardKnoxville$47K
- Kelsey MartinNashville$42K
- Barbara BrownNashville$36K
- Michelle GoochChattanooga$35K
- Elizabeth DavidsonNashville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.